(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $7.33
发出时间: 15 Feb 2024 @ 02:17
回报率: 44.20%
上一信号: Feb 14 - 22:30
上一信号:
回报率: 6.23 %
Live Chart Being Loaded With Signals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases...
Stats | |
---|---|
今日成交量 | 193 217 |
平均成交量 | 475 155 |
市值 | 273.83M |
EPS | $0 ( 2024-03-06 ) |
下一个收益日期 | ( $-1.080 ) 2024-05-08 |
Last Dividend | $0.0690 ( 2017-09-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.740 |
ATR14 | $0.0200 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Sell | 972 | Restricted Stock Unit |
2024-02-26 | Weiner David B. | Sell | 972 | Restricted Stock Unit |
INSIDER POWER |
---|
61.43 |
Last 100 transactions |
Buy: 3 683 868 | Sell: 932 723 |
音量 相关性
Inovio Pharmaceuticals 相关性 - 货币/商品
Inovio Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $832 010 |
毛利润: | $-2.67M (-321.09 %) |
EPS: | $-6.09 |
FY | 2023 |
营收: | $832 010 |
毛利润: | $-2.67M (-321.09 %) |
EPS: | $-6.09 |
FY | 2022 |
营收: | $10.26M |
毛利润: | $4.77M (46.44 %) |
EPS: | $-14.47 |
FY | 2021 |
营收: | $1.77M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.450 |
Financial Reports:
No articles found.
Inovio Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0690 | 2017-06-28 |
Last Dividend | $0.0690 | 2017-09-28 |
Next Dividend | $0 | N/A |
Payout Date | 2017-10-16 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | $0.276 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.17 | -- |
Div. Sustainability Score | 2.18 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.449 | -- |
Year | Amount | Yield |
---|---|---|
2017 | $0.276 | 3.90% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 3 430.55 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 16.50 | 1.200 | 10.00 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 18.29 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.60 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.47 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.336 | 1.500 | 9.24 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.175 | -1.500 | 7.09 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -241.59 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -5.80 | 2.00 | -1.932 | -3.86 | [0 - 30] |
freeCashFlowPerShareTTM | -5.81 | 2.00 | -2.90 | -5.81 | [0 - 20] |
debtEquityRatioTTM | 0.257 | -1.500 | 8.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -38.10 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -173.00 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -4.37 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00481 | 0.800 | -3.30 | -2.64 | [0.5 - 2] |
Total Score | 2.18 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0.0844 | 1.000 | -0.0925 | 0 | [1 - 100] |
returnOnEquityTTM | 18.29 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -5.81 | 2.00 | -1.936 | -5.81 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -5.80 | 2.00 | -1.932 | -3.86 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0000652 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -158.77 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.283 |
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。